Last reviewed · How we verify
Cardiogenic shock
Approved treatments
- Dobutamine Hydrochloride In Dextrose 5% In Plastic Container · Pfizer Inc.
Direct-acting inotropic agent stimulating cardiac beta-receptors with mild chronotropic and vasodilative effects. - Dobutamine Hydrochloride In Dextrose 5% In Plastic Container
- Dobutamin · Competence Network for Congenital Heart Defects
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Cardiogenic shock patent landscape — cliff calendar, originator estates, attackable patents
- Cardiogenic shock treatment landscape brief
- Cardiogenic shock treatment updates RSS
Frequently asked questions about Cardiogenic shock
What drugs treat Cardiogenic shock?
Tracked treatments include Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Dobutamin.
What is the treatment for Cardiogenic shock?
Standard treatment for Cardiogenic shock includes Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Dobutamin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Cardiogenic shock patent cliff · Cardiogenic shock CI report
- Treatment: Dobutamine Hydrochloride In Dextrose 5% In Plastic Container · Pfizer Inc.
- Treatment: Dobutamine Hydrochloride In Dextrose 5% In Plastic Container
- Treatment: Dobutamin · Competence Network for Congenital Heart Defects
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing